Camurus
Research Camurus (CAMX.ST) on Bullrun: market cap SEK 39.51B, P/E 58.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCAMX.ST
- ExchangeXSTO
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 39.51B
- P/E58.7
- Financial periodQ2 2026
- RevenueSEK 702.08M
- Net incomeSEK 240.83M
- Free cash flowSEK 193.13M
- Gross margin93.7%
Valuation Snapshot
latest market cap is SEK 39.51B; P/E is 58.7.
Peer valuation comparison
Latest P/E is 58.66x versus a Healthcare sector median of 24.64x (138.0% above).
Latest P/E is 58.66x versus a Sweden median of 18.18x (222.6% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 39.51B | 58.7 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Camurus
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Camurus's market cap?
Camurus's market capitalization is SEK 39.51B.
What is Camurus's P/E ratio?
Camurus's price-to-earnings (P/E) ratio is 58.7.
What does Camurus do?
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder.